Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms - Short running title: Ebola SARS-CoV-2 inhibitors

Puhl, Ana C.; Fritch, Ethan James; Lane, Thomas R.; Tse, Longping Victor; Yount, Boyd L.; Sacramento, Carol Queiroz; Tavella, Tatyana Almeida; Costa, Fabio Trindade Maranhão; Weston, Stuart; Logue, James; Frieman, Matthew; Premkumar, Lakshmanane; Pearce, Kenneth H.; Hurst, Brett L.; Andrade, Carolina Horta; Levi, James A.; Johnson, Nicole J.; Kisthardt, Samantha C.; Scholle, Frank; Souza, Thiago Moreno L.; Moorman, Nathaniel John; Baric, Ralph S.; Madrid, Peter; Ekins, Sean

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms - Short running title: Ebola SARS-CoV-2 inhibitors

Detalhes bibliográficos
Autor(a) principal:	Puhl, Ana C.
Data de Publicação:	2021
Outros Autores:	Fritch, Ethan James, Lane, Thomas R., Tse, Longping Victor, Yount, Boyd L., Sacramento, Carol Queiroz, Tavella, Tatyana Almeida, Costa, Fabio Trindade Maranhão, Weston, Stuart, Logue, James, Frieman, Matthew, Premkumar, Lakshmanane, Pearce, Kenneth H., Hurst, Brett L., Andrade, Carolina Horta, Levi, James A., Johnson, Nicole J., Kisthardt, Samantha C., Scholle, Frank, Souza, Thiago Moreno L., Moorman, Nathaniel John, Baric, Ralph S., Madrid, Peter, Ekins, Sean
Tipo de documento:	Artigo
Idioma:	eng
Título da fonte:	Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo:	https://www.arca.fiocruz.br/handle/icict/50788
Resumo:	Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive. Lab 3510, Raleigh, NC 27606, USA.

Metadados do item

id	CRUZ_be24d9b38cdfc255792b40ea09b4d4c0
oai_identifier_str	oai:www.arca.fiocruz.br:icict/50788
network_acronym_str	CRUZ
network_name_str	Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str	2135
spelling	Puhl, Ana C.Fritch, Ethan JamesLane, Thomas R.Tse, Longping VictorYount, Boyd L.Sacramento, Carol QueirozTavella, Tatyana AlmeidaCosta, Fabio Trindade MaranhãoWeston, StuartLogue, JamesFrieman, MatthewPremkumar, LakshmananePearce, Kenneth H.Hurst, Brett L.Andrade, Carolina HortaLevi, James A.Johnson, Nicole J.Kisthardt, Samantha C.Scholle, FrankSouza, Thiago Moreno L.Moorman, Nathaniel JohnBaric, Ralph S.Madrid, PeterEkins, Sean2022-01-17T17:49:44Z2022-01-17T17:49:44Z2021PUHL, Ana C. et al. Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV‑2 and Potential Mechanisms. Short running title: Ebola SARS-CoV-2 inhibitors. ACS OMEGA, v. 6, p. 7454-7468, Dec. 2021.2470-1343https://www.arca.fiocruz.br/handle/icict/5078810.1101/2020.12.01.407361engbioRxiv preprinthttps://www.arca.fiocruz.br/handle/icict/50764SARS-CoV-2AntiviralProteína de picoPironaridinaTiloroneQuinacrinaAntiviralSARS-CoV-2Spike proteinPyronaridineTiloroneQuinacrineRepurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms - Short running title: Ebola SARS-CoV-2 inhibitorsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleCollaborations Pharmaceuticals, Inc., 840 Main Campus Drive. Lab 3510, Raleigh, NC 27606, USA.Department of Microbiology and Immunology, University of North Carolina School of Medicine. Chapel Hill NC 27599, USA.Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive. Lab 3510, Raleigh, NC 27606, USA.University of North Carolina School of Medicine. Department of Epidemiology. Chapel Hill NC 27599, USA.University of North Carolina School of Medicine. Department of Epidemiology. Chapel Hill NC 27599, USA.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil.Universidade de Campinas. Departamento de Genética, Evolução, Microbiologia e Imunologia. Laboratório de Doenças Tropicais Dr. Luiz Jacinto da Silva. Campinas, SP, Brasil.Universidade de Campinas. Departamento de Genética, Evolução, Microbiologia e Imunologia. Laboratório de Doenças Tropicais Dr. Luiz Jacinto da Silva. Campinas, SP, Brasil.University of Maryland School of Medicine. Department of Microbiology and Immunology. Baltimore, Maryland, USA.University of Maryland School of Medicine. Department of Microbiology and Immunology. Baltimore, Maryland, USA.University of Maryland School of Medicine. Department of Microbiology and Immunology. Baltimore, Maryland, USA.Department of Microbiology and Immunology, University of North Carolina School of Medicine. Chapel Hill NC 27599, USA.Center for Integrative Chemical Biology and Drug Discovery, Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA / iUNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599, USA.Institute for Antiviral Research, Utah State University, Logan, UT, USA / Department of Animal, Dairy and Veterinary Sciences, Utah State University, Logan, UT, USA.Universidade de Campinas. Departamento de Genética, Evolução, Microbiologia e Imunologia. Laboratório de Doenças Tropicais Dr. Luiz Jacinto da Silva. Campinas, SP, Brasil / Universidade Federal de Goiás. Faculade de Farmácia. LabMol - Laboratório de Modelagem Molecular e Design de Fármacos. Goiânia, GO, Brasil.Department of Biological Sciences, North Carolina State University. Raleigh, NC, USA.Department of Biological Sciences, North Carolina State University. Raleigh, NC, USA.Department of Biological Sciences, North Carolina State University. Raleigh, NC, USA.Department of Biological Sciences, North Carolina State University. Raleigh, NC, USA.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Rio de Janeiro, RJ, Brasil.Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA / Center for Integrative Chemical Biology and Drug Discovery, Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA / Rapidly Emerging Antiviral Drug Discovery Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.Department of Microbiology and Immunology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA / Department of Epidemiology, University of North Carolina School of Medicine, Chapel Hill NC 27599, USA / Rapidly Emerging Antiviral Drug Discovery Initiative, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.SRI International, 333 Ravenswood Avenue, Menlo Park. CA 94025, USA.Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510, Raleigh, NC 27606, USA.SARS-CoV-2 is a newly identified virus that has resulted in over 1.3 M deaths globally and over 59 M cases globally to date. Small molecule inhibitors that reverse disease severity have proven difficult to discover. One of the key approaches that has been widely applied in an effort to speed up the translation of drugs is drug repurposing. A few drugs have shown in vitro activity against Ebola virus and demonstrated activity against SARS-CoV-2 in vivo. Most notably the RNA polymerase targeting remdesivir demonstrated activity in vitro and efficacy in the early stage of the disease in humans. Testing other small molecule drugs that are active against Ebola virus would seem a reasonable strategy to evaluate their potential for SARS-CoV-2. We have previously repurposed pyronaridine, tilorone and quinacrine (from malaria, influenza, and antiprotozoal uses, respectively) as inhibitors of Ebola and Marburg virus in vitro in HeLa cells and of mouse adapted Ebola virus in mouse in vivo. We have now tested these three drugs in various cell lines (VeroE6, Vero76, Caco-2, Calu-3, A549-ACE2, HUH-7 and monocytes) infected with SARS-CoV-2 as well as other viruses (including MHV and HCoV 229E). The compilation of these results indicated considerable variability in antiviral activity observed across cell lines. We found that tilorone and pyronaridine inhibited the virus replication in A549-ACE2 cells with IC50 values of 180 nM and IC50 198 nM, respectively. We have also tested them in a pseudovirus assay and used microscale thermophoresis to test the binding of these molecules to the spike protein. They bind to spike RBD protein with Kd values of 339 nM and 647 nM,justifying in vivo evaluation. We also provide novel insights into their mechanism which is likely lysosomotropic. respectively. Human Cmax for pyronaridine and quinacrine is greater than the IC50 hence.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/50788/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINAL2 - Puhla_Ana_etal_IOC_CDTS_COVID-19_2021.pdf2 - Puhla_Ana_etal_IOC_CDTS_COVID-19_2021.pdfapplication/pdf383777https://www.arca.fiocruz.br/bitstream/icict/50788/2/2%20-%20Puhla_Ana_etal_IOC_CDTS_COVID-19_2021.pdfd5c4df8c11f8d0058bdd5da49da1d645MD52icict/507882023-01-27 16:15:21.337oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-01-27T19:15:21Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms - Short running title: Ebola SARS-CoV-2 inhibitors
title	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms - Short running title: Ebola SARS-CoV-2 inhibitors
spellingShingle	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms - Short running title: Ebola SARS-CoV-2 inhibitors Puhl, Ana C. SARS-CoV-2 Antiviral Proteína de pico Pironaridina Tilorone Quinacrina Antiviral SARS-CoV-2 Spike protein Pyronaridine Tilorone Quinacrine
title_short	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms - Short running title: Ebola SARS-CoV-2 inhibitors
title_full	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms - Short running title: Ebola SARS-CoV-2 inhibitors
title_fullStr	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms - Short running title: Ebola SARS-CoV-2 inhibitors
title_full_unstemmed	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms - Short running title: Ebola SARS-CoV-2 inhibitors
title_sort	Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms - Short running title: Ebola SARS-CoV-2 inhibitors
author	Puhl, Ana C.
author_facet	Puhl, Ana C. Fritch, Ethan James Lane, Thomas R. Tse, Longping Victor Yount, Boyd L. Sacramento, Carol Queiroz Tavella, Tatyana Almeida Costa, Fabio Trindade Maranhão Weston, Stuart Logue, James Frieman, Matthew Premkumar, Lakshmanane Pearce, Kenneth H. Hurst, Brett L. Andrade, Carolina Horta Levi, James A. Johnson, Nicole J. Kisthardt, Samantha C. Scholle, Frank Souza, Thiago Moreno L. Moorman, Nathaniel John Baric, Ralph S. Madrid, Peter Ekins, Sean
author_role	author
author2	Fritch, Ethan James Lane, Thomas R. Tse, Longping Victor Yount, Boyd L. Sacramento, Carol Queiroz Tavella, Tatyana Almeida Costa, Fabio Trindade Maranhão Weston, Stuart Logue, James Frieman, Matthew Premkumar, Lakshmanane Pearce, Kenneth H. Hurst, Brett L. Andrade, Carolina Horta Levi, James A. Johnson, Nicole J. Kisthardt, Samantha C. Scholle, Frank Souza, Thiago Moreno L. Moorman, Nathaniel John Baric, Ralph S. Madrid, Peter Ekins, Sean
author2_role	author author author author author author author author author author author author author author author author author author author author author author author
dc.contributor.author.fl_str_mv	Puhl, Ana C. Fritch, Ethan James Lane, Thomas R. Tse, Longping Victor Yount, Boyd L. Sacramento, Carol Queiroz Tavella, Tatyana Almeida Costa, Fabio Trindade Maranhão Weston, Stuart Logue, James Frieman, Matthew Premkumar, Lakshmanane Pearce, Kenneth H. Hurst, Brett L. Andrade, Carolina Horta Levi, James A. Johnson, Nicole J. Kisthardt, Samantha C. Scholle, Frank Souza, Thiago Moreno L. Moorman, Nathaniel John Baric, Ralph S. Madrid, Peter Ekins, Sean
dc.subject.other.pt_BR.fl_str_mv	SARS-CoV-2 Antiviral Proteína de pico Pironaridina Tilorone Quinacrina
topic	SARS-CoV-2 Antiviral Proteína de pico Pironaridina Tilorone Quinacrina Antiviral SARS-CoV-2 Spike protein Pyronaridine Tilorone Quinacrine
dc.subject.en.pt_BR.fl_str_mv	Antiviral SARS-CoV-2 Spike protein Pyronaridine Tilorone Quinacrine
description	Collaborations Pharmaceuticals, Inc., 840 Main Campus Drive. Lab 3510, Raleigh, NC 27606, USA.
publishDate	2021
dc.date.issued.fl_str_mv	2021
dc.date.accessioned.fl_str_mv	2022-01-17T17:49:44Z
dc.date.available.fl_str_mv	2022-01-17T17:49:44Z
dc.type.status.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv	info:eu-repo/semantics/article
format	article
status_str	publishedVersion
dc.identifier.citation.fl_str_mv	PUHL, Ana C. et al. Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV‑2 and Potential Mechanisms. Short running title: Ebola SARS-CoV-2 inhibitors. ACS OMEGA, v. 6, p. 7454-7468, Dec. 2021.
dc.identifier.uri.fl_str_mv	https://www.arca.fiocruz.br/handle/icict/50788
dc.identifier.issn.pt_BR.fl_str_mv	2470-1343
dc.identifier.doi.none.fl_str_mv	10.1101/2020.12.01.407361
identifier_str_mv	PUHL, Ana C. et al. Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV‑2 and Potential Mechanisms. Short running title: Ebola SARS-CoV-2 inhibitors. ACS OMEGA, v. 6, p. 7454-7468, Dec. 2021. 2470-1343 10.1101/2020.12.01.407361
url	https://www.arca.fiocruz.br/handle/icict/50788
dc.language.iso.fl_str_mv	eng
language	eng
dc.relation.hasversion.pt_BR.fl_str_mv	https://www.arca.fiocruz.br/handle/icict/50764
dc.rights.driver.fl_str_mv	info:eu-repo/semantics/openAccess
eu_rights_str_mv	openAccess
dc.publisher.none.fl_str_mv	bioRxiv preprint
publisher.none.fl_str_mv	bioRxiv preprint
dc.source.none.fl_str_mv	reponame:Repositório Institucional da FIOCRUZ (ARCA) instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ
instname_str	Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str	FIOCRUZ
institution	FIOCRUZ
reponame_str	Repositório Institucional da FIOCRUZ (ARCA)
collection	Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv	https://www.arca.fiocruz.br/bitstream/icict/50788/1/license.txt https://www.arca.fiocruz.br/bitstream/icict/50788/2/2%20-%20Puhla_Ana_etal_IOC_CDTS_COVID-19_2021.pdf
bitstream.checksum.fl_str_mv	5a560609d32a3863062d77ff32785d58 d5c4df8c11f8d0058bdd5da49da1d645
bitstream.checksumAlgorithm.fl_str_mv	MD5 MD5
repository.name.fl_str_mv	Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv	repositorio.arca@fiocruz.br
_version_	1813009083238711296

Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms - Short running title: Ebola SARS-CoV-2 inhibitors

Registros relacionados